Positive topline results in a Phase II clinical trial of a licensee’s alopecia treatment using the ProSilic® variant of SiSaf’s Bio-Courier® delivery technology Formulation of the small molecule drug...
GUILDFORD, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA therapeutics company, is pleased to announce the publication in the peer-reviewed journal Molecular Therapy Nucleic...
GUILDFORD, England, July 13, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd announces that it has appointed Nikos Tzagkarakis in the newly created role of Chief A.I....
GUILDFORD, England, May 15, 2023 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA delivery and therapeutics company, announces that SIS-101-ADO, its siRNA therapeutic for patients with Autosomal Dominant...
GUILDFORD, England, April 05, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announced that it has appointed Dr. Richard Goodfellow to its Board of Directors. nnRichard draws on four decades of international experience across the biotechnology and pharmaceutical sectors, including leadership roles in business development and Chief Executive of Scancell, an AIM listed clinical stage immuno-oncology biopharmaceutical company. He has acted as a consultant to SiSaf since 2021. nnSiSaf’s founder and CEO Dr. Suzanne Saffie-Siebert said, “I’m delighted to welcome Richard to our Board. As we are building and expanding our commercial partnerships and in-house pipeline of RNA therapeutics, Richard’s vast range of experience in the life science industry will be a valuable addition to SiSaf’s board and will support the company’s further growth.” nnDr Richard Goodfellow commented on his appointment as Non-Executive Director, “I welcome the opportunity to join SiSaf’s Board. Having worked with Suzanne and her team in an advisory capacity for the past two years, I believe the potential of SiSaf’s next-generation delivery technology for life-changing RNA treatments is significant. I look forward to taking on a strategic role to help the company make the most of the opportunities this offers.” nnSiSaf’s proprietary Bio-Courier technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon. Its lead product SIS-101-ADO, an siRNA therapeutic for patients with Autosomal Dominant Osteopetrosis Type 2 (ADO2), a rare genetic skeletal disorder, began the U.S. FDA Regulatory process to obtain an Orphan Drug Designation in October 2022
SiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer